Gelteq Past Earnings Performance
Past criteria checks 0/6
Gelteq's earnings have been declining at an average annual rate of -33.4%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 2.6% per year.
Key information
-33.4%
Earnings growth rate
-18.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -2.6% |
| Return on equity | -23.5% |
| Net Margin | -2,414.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Gelteq makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -4 | 1 | 0 |
| 31 Mar 24 | 0 | -3 | 1 | 0 |
| 30 Jun 23 | 0 | -4 | 1 | 1 |
| 31 Mar 23 | 1 | -4 | 1 | 1 |
| 30 Jun 22 | 0 | -3 | 1 | 1 |
| 31 Mar 22 | 0 | -2 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 0 | 0 |
Quality Earnings: GELS is currently unprofitable.
Growing Profit Margin: GELS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GELS is unprofitable, and losses have increased over the past 5 years at a rate of 33.4% per year.
Accelerating Growth: Unable to compare GELS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GELS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: GELS has a negative Return on Equity (-23.47%), as it is currently unprofitable.